Invesco Ltd. Krystal Biotech, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 365,551 shares of KRYS stock, worth $65.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

365,551

Previous 275,077 32.89%

Holding current value

$65.1 Million

Previous $50.5 Million 31.59%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$174.7 - $213.66 $15.8 Million - $19.3 Million	90,474 Added 32.89%	365,551 $66.5 Million
Q2 2024 Aug 13, 2024	BUY	$153.12 - $183.64 $28.4 Million - $34.1 Million	185,449 Added 206.91%	275,077 $50.5 Million
Q1 2024 May 14, 2024	BUY	$108.01 - $179.35 $3.82 Million - $6.35 Million	35,399 Added 65.28%	89,628 $15.9 Million
Q4 2023 Feb 12, 2024	BUY	$96.0 - $128.29 $962,880 - $1.29 Million	10,030 Added 22.69%	54,229 $6.73 Million
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $2.28 Million - $2.74 Million	-21,009 Reduced 32.22%	44,199 $5.13 Million
Q2 2023 Aug 11, 2023	BUY	$78.48 - $130.32 $1.07 Million - $1.78 Million	13,628 Added 26.42%	65,208 $7.66 Million
Q1 2023 May 12, 2023	BUY	$72.39 - $84.27 $1.7 Million - $1.98 Million	23,537 Added 83.93%	51,580 $4.13 Million
Q4 2022 Feb 13, 2023	SELL	$63.14 - $79.9 $1.49 Million - $1.88 Million	-23,565 Reduced 45.66%	28,043 $2.22 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $2.75 Million - $3.5 Million	42,454 Added 463.78%	51,608 $3.6 Million
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $68,697 - $103,151	1,404 Added 18.12%	9,154 $600,000
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $3,587 - $4,975	69 Added 0.9%	7,750 $515,000
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $18,113 - $40,149	-455 Reduced 5.59%	7,681 $538,000
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $48,421 - $66,817	931 Added 12.92%	8,136 $425,000
Q2 2021 Aug 17, 2021	BUY	$62.14 - $81.82 $214,631 - $282,606	3,454 Added 92.08%	7,205 $489,000
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $222,884 - $320,560	3,751 New	3,751 $289,000
Q2 2020 Aug 14, 2020	SELL	$37.03 - $60.0 $1.28 Million - $2.08 Million	-34,701 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$35.02 - $65.64 $1.67 Million - $3.13 Million	-47,632 Reduced 57.85%	34,701 $1.5 Million
Q4 2019 Feb 14, 2020	BUY	$33.17 - $65.23 $1.17 Million - $2.29 Million	35,123 Added 74.4%	82,333 $4.56 Million
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $1.64 Million - $2.42 Million	47,210 New	47,210 $1.64 Million
Q1 2019 May 15, 2019	SELL	$19.86 - $32.9 $935,664 - $1.55 Million	-47,113 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $708,108 - $1.2 Million	47,113 New	47,113 $979,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account